Solasia Pharma K.K. Faces Revenue Decline
Company Announcements

Solasia Pharma K.K. Faces Revenue Decline

Solasia Pharma KK (JP:4597) has released an update.

Solasia Pharma K.K. reports significant year-on-year revenue decline in the first six months of 2024, with a decrease in profit and basic earnings per share. The company maintains a stable equity ratio, while its forward-looking revenue and profit forecasts suggest a potential rebound by the end of the fiscal year. No dividends were paid or forecasted for the fiscal year, reflecting the company’s cautious financial management amid its current performance.

For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskSolasia Pharma Nears DARVIAS Licensing Deal in China
TipRanks Japan Auto-Generated NewsdeskSolasia Pharma’s Strategic Progress in Global Markets
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App